Xi'an Zhouliangmingkang Biomedical Technology

Xi'an Zhouliangmingkang Biomedical Technology is a clinical-stage biotechnology company based in Xi'an, China, dedicated to the development of innovative ophthalmic therapeutics. The company's lead candidate, ZL-001, is a novel small molecule currently in Phase 2 clinical trials for the treatment of dry eye disease. Zhouliangmingkang focuses on addressing significant unmet medical needs in the eye care sector through internal research and development. The firm is supported by regional venture capital and is led by a team of experienced pharmaceutical scientists. Its strategic goal is to provide effective and accessible treatments for patients suffering from chronic ocular conditions.